<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMJ Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMJ Case Rep</journal-id>
      <journal-id journal-id-type="hwp">casereports</journal-id>
      <journal-id journal-id-type="publisher-id">bmjcasereports</journal-id>
      <journal-title-group>
        <journal-title>BMJ Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1757-790X</issn>
      <publisher>
        <publisher-name>BMJ Publishing Group</publisher-name>
        <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28069788</article-id>
      <article-id pub-id-type="pmc">5256449</article-id>
      <article-id pub-id-type="publisher-id">bcr-2016-218353</article-id>
      <article-id pub-id-type="doi">10.1136/bcr-2016-218353</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
        <subj-group subj-group-type="case-report-type">
          <subject>Rare Disease</subject>
        </subj-group>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>1506</subject>
          <subject>1523</subject>
        </subj-group>
        <subj-group subj-group-type="search-fields">
          <subject>Male</subject>
          <subject>71-80 years</subject>
          <subject>Other Asian</subject>
          <subject>Japan</subject>
        </subj-group>
        <series-title>Case Report</series-title>
      </article-categories>
      <title-group>
        <article-title>Proteinase 3-antineutrophil cytoplasmic antibody-positive ulcerative colitis presenting with abducens neuropathy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kirito</surname>
            <given-names>Yuki</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Daisuke</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uchiyama</surname>
            <given-names>Tsuyoshi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff><addr-line>Department of Neurology</addr-line>, <institution>Seirei Hamamatu General Hospital</institution>, <addr-line>Hamamatsu, Shizuoka</addr-line>, <country>Japan</country></aff>
      <author-notes>
        <corresp><label>Correspondence to</label> Dr Daisuke Yamamoto; <email>daisuke-yama@sis.seirei.or.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>09</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>2017</volume>
      <elocation-id>bcr2016218353</elocation-id>
      <history>
        <date date-type="accepted">
          <day>23</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>2017 BMJ Publishing Group Ltd</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:href="bcr-2016-218353.pdf"/>
      <abstract>
        <p>A 72-year-old man with ulcerative colitis (UC) presented with complete left abducens nerve palsy. Although MRI showed no significant changes, cerebrospinal fluid analysis revealed pleocytosis and elevated protein and interleukin (IL)-6 levels. His serum proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) level was also elevated to 31.1&#x2005;U/mL, but granulomatosis with polyangiitis was not observed. On the basis of the diagnosis of autoimmune cranial neuropathy, he was treated with steroid therapy. While tapering steroid therapy, his serum PR3-ANCA levels; cerebrospinal fluid findings, including IL-6 levels; and symptoms improved. Serum PR3-ANCA could be a useful parameter of neurological disorders associated with ANCA-positive UC.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>special-feature</meta-name>
          <meta-value>unlocked</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Background</title>
      <p>The association of ulcerative colitis (UC) with antineutrophil cytoplasmic antibodies (ANCAs) has been studied. ANCA testing is helpful in distinguishing UC from Crohn's disease.<xref rid="R1" ref-type="bibr">1</xref>
<xref rid="R2" ref-type="bibr">2</xref> Although UC-associated ANCAs do not have the potential for development of systemic vasculitis or for neutrophil activation,<xref rid="R3" ref-type="bibr">3</xref> the pathogenic role of ANCAs in inflammatory bowel diseases remains unknown. It is also unknown whether the ANCA level shows simultaneous changes with UC disease activity. We describe a case of unilateral abducens nerve palsy associated with proteinase 3 (PR3)-ANCA-positive UC, where serum PR3-ANCA levels and neurological symptoms improved simultaneously during the course of tapering steroid therapy.</p>
    </sec>
    <sec id="s2">
      <title>Case presentation</title>
      <p>A 72-year-old man with a 5-year history of UC was referred to our hospital reporting double vision that had started 40&#x2005;days previously. Since his UC symptoms were unresponsive to steroid therapy, he was treated with vedolizumab and his UC was stable on admission to our hospital. Clinical examination revealed complete left abducens nerve palsy, with no evidence of uveitis and a normal fundus. No other abnormal neurological findings were detected. His temperature was normal.</p>
    </sec>
    <sec id="s3">
      <title>Investigations</title>
      <p>His C reactive protein (2.2&#x2005;mg/dL) and PR3-ANCA (31.1&#x2005;U/mL; ELISA) levels were elevated. Cerebrospinal fluid (CSF) analysis revealed pleocytosis (25/mm<sup>3</sup>), elevated protein (127&#x2005;mg/dL) and interleukin (IL)-6 (437&#x2005;pg/mL) levels, and normal glucose and intracranial pressure levels. Results of extensive microbiological and immunological studies were normal. Antibodies and antigens for HIV were negative. CT of the chest, abdomen and pelvis were unremarkable, except for findings of UC. Brain MRI showed a swollen nasal cavity mucosal membrane and no significant change in the left abducens nerve and around it (<xref ref-type="fig" rid="BCR2016218353F1">figure 1</xref>). Magnetic resonance angiography showed no stenotic lesions. Nasal cavity mucosal membrane biopsy showed no specific changes and no evidence of granuloma. There was no evidence of granulomatosis with polyangiitis, and the lungs and kidneys were normal.</p>
      <fig id="BCR2016218353F1" orientation="portrait" position="float">
        <label>Figure&#xA0;1</label>
        <caption>
          <p>(A) T<sub>2</sub>-weighted axial (1.5&#x2005;T; TR, 3160&#x2005;ms; TE, 183.3&#x2005;ms) images show no significant changes in the left abducens nerve or around it. (B) T<sub>2</sub>-weighted axial (1.5&#x2005;T; TR, 4025&#x2005;ms; TE, 88.4&#x2005;ms) images showed a swollen nasal cavity mucosal membrane (arrow).</p>
        </caption>
        <graphic xlink:href="bcr2016218353f01"/>
      </fig>
    </sec>
    <sec id="s4">
      <title>Treatment</title>
      <p>On the basis of diagnosis of autoimmune cranial mononeuritis of the abducens nerve, high-dose methylprednisolone (1000&#x2005;mg/day) steroid therapy was initiated intravenously and continued for 3&#x2005;days (<xref ref-type="fig" rid="BCR2016218353F2">figure 2</xref>). The left abducens nerve palsy partially improved; therefore, another course of high-dose methylprednisolone steroid therapy was continued followed by oral prednisolone (20&#x2005;mg/day) steroid therapy.</p>
      <fig id="BCR2016218353F2" orientation="portrait" position="float">
        <label>Figure&#xA0;2</label>
        <caption>
          <p>Two courses of high-dose methylprednisolone (1000&#x2005;mg/day for 3&#x2005;days) were initiated intravenously followed by oral prednisolone (20&#x2005;mg/day). After the steroid therapy was started, the left abducens nerve palsy and CSF findings improved. During the course of tapering steroid therapy, serum PR3-ANCA and CSF IL-6 levels decreased. Four months after symptom onset, the left abducens nerve palsy was completely resolved with treatment of oral prednisolone (10&#x2005;mg/day). CSF, cerebrospinal fluid; mPSL, methylprednisolone; PSL, prednisolone.</p>
        </caption>
        <graphic xlink:href="bcr2016218353f02"/>
      </fig>
    </sec>
    <sec id="s5">
      <title>Outcome and follow-up</title>
      <p>Two months from its onset, the left abducens nerve palsy along with CSF findings had improved. During the course of tapering steroid therapy, serum PR3-ANCA and CSF IL-6 (1.2&#x2005;pg/mL) levels decreased. Four months after the onset, the left abducens nerve palsy had completely resolved with the treatment of oral prednisolone (10&#x2005;mg/day).</p>
    </sec>
    <sec sec-type="discussion" id="s6">
      <title>Discussion</title>
      <p>We report a case of unilateral abducens nerve palsy associated with PR3-ANCA-positive UC caused by autoimmune mechanisms. Neurological disorders associated with UC are uncommon, although other extraintestinal manifestations have been described. Neurological disorders have been reported in 3% of cases with inflammatory bowel disease,<xref rid="R4" ref-type="bibr">4</xref> and only a few cases of cranial neuropathy associated with UC have been reported (<xref ref-type="table" rid="BCR2016218353TB1">table 1</xref>).<xref rid="R5" ref-type="bibr">5&#x2013;9</xref> Some cases of olfactory dysfunction, optic neuritis and sensorineural hearing loss have been reported.</p>
      <table-wrap id="BCR2016218353TB1" orientation="portrait" position="float">
        <label>Table&#xA0;1</label>
        <caption>
          <p>Case reports of cranial nerve disorder associated with UC</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead valign="bottom">
            <tr>
              <th align="left" rowspan="1" colspan="1">Author</th>
              <th align="left" rowspan="1" colspan="1">Cranial nerve lesion</th>
              <th align="left" rowspan="1" colspan="1">Suspected mechanism</th>
              <th align="left" rowspan="1" colspan="1">Treatment</th>
              <th align="left" rowspan="1" colspan="1">Clinical course</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Steinbach <italic>et al</italic><xref rid="R5" ref-type="bibr">5</xref></td>
              <td rowspan="1" colspan="1">Olfactory nerve</td>
              <td rowspan="1" colspan="1">Autoimmune</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Alexandre <italic>et al</italic><xref rid="R6" ref-type="bibr">6</xref></td>
              <td rowspan="1" colspan="1">Optic nerve</td>
              <td rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Autoimmune</p></list-item><list-item><p>Anti-TNF therapy associated</p></list-item></list></td>
              <td rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Steroid</p></list-item><list-item><p>Steroid</p></list-item></list></td>
              <td rowspan="1" colspan="1">Improvement<break/>Improvement</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Present study</td>
              <td rowspan="1" colspan="1">Abducens nerve</td>
              <td rowspan="1" colspan="1">Autoimmune</td>
              <td rowspan="1" colspan="1">Steroid</td>
              <td rowspan="1" colspan="1">Improvement</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gondim Fde <italic>et al</italic><xref rid="R7" ref-type="bibr">7</xref></td>
              <td rowspan="1" colspan="1">Facial nerve</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kumar <italic>et al</italic><xref rid="R8" ref-type="bibr">8</xref></td>
              <td rowspan="1" colspan="1">Vestibulocochlear nerve</td>
              <td rowspan="1" colspan="1">Autoimmune</td>
              <td rowspan="1" colspan="1">Steroid</td>
              <td rowspan="1" colspan="1">Improvement</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kawashima <italic>et al</italic><xref rid="R9" ref-type="bibr">9</xref></td>
              <td rowspan="1" colspan="1">Hypogrosal nerve</td>
              <td rowspan="1" colspan="1">Autoimmune</td>
              <td rowspan="1" colspan="1">Steroid</td>
              <td rowspan="1" colspan="1">Improvement</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>TNF, tumour necrosis factor; UC, ulcerative colitis.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Biological therapies may cause neurological complications. Central nervous system vasculitis secondary to anti-tumour necrosis factor therapy has been reported, including other diseases.<xref rid="R4" ref-type="bibr">4</xref> The safety of vedolizumab with respect to neurological complications for UC has been evaluated.<xref rid="R10" ref-type="bibr">10</xref> Our patient developed abducens nerve palsy 10&#x2005;months after initiating vedolizumab therapy. His neurological symptoms improved with steroid therapy without cessation of the vedolizumab, but the possibility of an association with vedolizumab in the present case cannot be excluded.</p>
      <p>Pathophysiologically, three major mechanisms are reported to cause neurological disorders associated with UC: (i) cerebrovascular disease as a consequence of thrombosis and thromboembolism, (ii) systemic and cerebral vasculitis and (iii) probably immune-mediated neuropathy and cerebral demyelination.<xref rid="R11" ref-type="bibr">11</xref> There are no reports about CSF IL-6 levels in neurological complications associated with UC; however, simultaneous improvement of neurological symptoms along with decreasing CSF IL-6 levels and responsiveness to steroid therapy suggests inflammatory and autoimmune mechanisms in our patient.</p>
      <p>It is interesting that the serum PR3-ANCA level; CSF findings, including the IL-6 level; and neurological symptoms showed simultaneous improvement during the course of tapering steroid therapy in the present case. Clinical implications of PR3-ANCA levels in UC have not been defined. It has been suggested that the serum PR3-ANCA level could be a useful serological diagnostic marker for UC,<xref rid="R1" ref-type="bibr">1</xref>
<xref rid="R2" ref-type="bibr">2</xref> but it is not known whether or not the PR3-ANCA level and UC disease activity show simultaneous changes. Neurological disorders associated with UC may occur independent of the UC activity.<xref rid="R4" ref-type="bibr">4</xref>
<xref rid="R11" ref-type="bibr">11</xref>
<xref rid="R12" ref-type="bibr">12</xref> In our case, neurological symptoms developed independent of the UC disease activity, and the serum PR3-ANCA levels and neurological symptoms showed simultaneous improvement, indicating that the serum PR3-ANCA level may have been a useful parameter of the neurogenic complications accompanying ANCA-positive UC in the present case.</p>
      <p>We described a case of unilateral abducens nerve palsy associated with PR3-ANCA-positive UC where serum PR3-ANCA levels and neurological symptoms improved simultaneously during the course of tapering steroid therapy. Serum PR3-ANCA and CSF IL-6 levels appeared to be useful parameters of neurogenic complications in this patient. More studies are needed to define the role of PR3-ANCA in UC.</p>
      <boxed-text position="float" orientation="portrait">
        <caption>
          <title>Learning points</title>
        </caption>
        <list list-type="bullet">
          <list-item>
            <p>Neurological disorders associated with UC are uncommon.</p>
          </list-item>
          <list-item>
            <p>Neurological disorders associated with UC may occur independent of the UC activity.</p>
          </list-item>
          <list-item>
            <p>We describe a case of unilateral abducens nerve palsy associated with PR3-ANCA-positive UC, where serum PR3-ANCA levels and neurological symptoms improved simultaneously during the course of tapering steroid therapy.</p>
          </list-item>
          <list-item>
            <p>Serum PR3-ANCA level may have been a useful parameter of the neurogenic complications accompanying ANCA-positive UC in the present case, although the pathogenic role of PR3-ANCA in UC remains unknown.</p>
          </list-item>
        </list>
      </boxed-text>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Contributors:</bold> YK is a major contributor in writing the manuscript. DY and TU also treated the patient and interpreted the patient data. All authors read and approved the final manuscript.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p><bold>Competing interests:</bold> None declared.</p>
      </fn>
      <fn>
        <p><bold>Patient consent:</bold> Obtained.</p>
      </fn>
      <fn>
        <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>M</given-names></name>, <name><surname>Bogdanos</surname><given-names>DP</given-names></name>, <name><surname>Pavlidis</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease</article-title>. <source>Clin Chim Acta</source>
<year>2013</year>;<volume>424</volume>:<fpage>267</fpage>&#x2013;<lpage>73</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cca.2013.06.005">doi:10.1016/j.cca.2013.06.005</ext-link><pub-id pub-id-type="pmid">23806819</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arias-Loste</surname><given-names>MT</given-names></name>, <name><surname>Bonilla</surname><given-names>G</given-names></name>, <name><surname>Moraleja</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease</article-title>. <source>Clin Rev Allergy Immunol</source>
<year>2013</year>;<volume>45</volume>:<fpage>109</fpage>&#x2013;<lpage>16</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12016-012-8349-4">doi:10.1007/s12016-012-8349-4</ext-link><pub-id pub-id-type="pmid">23345025</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bart&#x16F;nkov&#xE1;</surname><given-names>J</given-names></name>, <name><surname>Tesar</surname><given-names>V</given-names></name>, <name><surname>Sediv&#xE1;</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies</article-title>. <source>Clin Immunol</source>
<year>2003</year>;<volume>106</volume>:<fpage>73</fpage>&#x2013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">12672398</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casella</surname><given-names>G</given-names></name>, <name><surname>Tontini</surname><given-names>GE</given-names></name>, <name><surname>Bassotti</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Neurological disorders and inflammatory bowel diseases</article-title>. <source>World J Gastroenterol</source>
<year>2014</year>;<volume>20</volume>:<fpage>8764</fpage>&#x2013;<lpage>82</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3748/wjg.v20.i27.8764">doi:10.3748/wjg.v20.i27.8764</ext-link><pub-id pub-id-type="pmid">25083051</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbach</surname><given-names>S</given-names></name>, <name><surname>Reindl</surname><given-names>W</given-names></name>, <name><surname>Dempfle</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Smell and taste in inflammatory bowel disease</article-title>. <source>PLoS ONE</source>
<year>2013</year>;<volume>8</volume>:<fpage>e73454</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0073454">doi:10.1371/journal.pone.0073454</ext-link><pub-id pub-id-type="pmid">24086282</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>B</given-names></name>, <name><surname>Vandermeeren</surname><given-names>Y</given-names></name>, <name><surname>Dewit</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Optic neuritis associated or not with TNF antagonists in patients with inflammatory bowel disease</article-title>. <source>J Crohns Colitis.</source>
<year>2016</year>;<volume>10</volume>:<fpage>541</fpage>&#x2013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ecco-jcc/jjw003">doi:10.1093/ecco-jcc/jjw003</ext-link><pub-id pub-id-type="pmid">26759360</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gondim Fde</surname><given-names>A</given-names></name>, <name><surname>Oliveira</surname><given-names>GR</given-names></name>, <name><surname>Teles</surname><given-names>BC</given-names></name><etal/></person-group>
<article-title>A case-control study of the prevalence of neurological diseases in inflammatory bowel disease (IBD)</article-title>. <source>Arq Neuropsiquiatr.</source>
<year>2015</year>;<volume>73</volume>:<fpage>119</fpage>&#x2013;<lpage>224</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/0004-282X20140223">doi:10.1590/0004-282X20140223</ext-link><pub-id pub-id-type="pmid">25742581</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>BN</given-names></name>, <name><surname>Smith</surname><given-names>MS</given-names></name>, <name><surname>Walsh</surname><given-names>RM</given-names></name><etal/></person-group>
<article-title>Sensorineural hearing loss in ulcerative colitis</article-title>. <source>Clin Otolaryngol Allied Sci</source>
<year>2000</year>;<volume>25</volume>:<fpage>143</fpage>&#x2013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">10816220</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawashima</surname><given-names>K</given-names></name>, <name><surname>Ishihara</surname><given-names>S</given-names></name>, <name><surname>Doi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Ulcerative colitis associated with isolated unilateral hypoglossal nerve palsy</article-title>. <source>Intern Med</source>
<year>2012</year>;<volume>51</volume>:<fpage>3135</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23154719</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombel</surname><given-names>JF</given-names></name>, <name><surname>Sands</surname><given-names>BE</given-names></name>, <name><surname>Rutgeerts</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>The safety of vedolizumab for ulcerative colitis and Crohn's disease</article-title>. <source>Gut</source>
<year>2016</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/gutjnl-2015-311079">doi:10.1136/gutjnl-2015-311079</ext-link></comment>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/gutjnl-2015-311079">doi:10.1136/gutjnl-2015-311079</ext-link></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>R</given-names></name>, <name><surname>Teich</surname><given-names>N</given-names></name></person-group>
<article-title>Neurologic manifestations of ulcerative colitis</article-title>. <source>Eur J Neurol</source>
<year>2007</year>;<volume>14</volume>:<fpage>483</fpage>&#x2013;<lpage>93</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1468-1331.2007.01718.x">doi:10.1111/j.1468-1331.2007.01718.x</ext-link><pub-id pub-id-type="pmid">17437605</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Losses</surname><given-names>A</given-names></name>, <name><surname>River</surname><given-names>Y</given-names></name>, <name><surname>Eliakim</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Neurologic aspects of inflammatory bowel disease</article-title>. <source>Neurology</source>
<year>1995</year>;<volume>45</volume>:<fpage>416</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">7898687</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
